SAN DIEGO—Older patients with type 2 diabetes have a significantly higher likelihood of experiencing a cardiovascular (CV) event within two years if they start treatment with a sulfonylurea drug than with metformin, researchers reported at the 71st Scientific Sessions of the American Diabetes Association.
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a new password.